During the corresponding time, 23andme Holding Co saw a revenue deteriorated by -37.92 % year on year, sequentially revenue fell by -46.97 %. While revenue at the 23andme Holding Co's corporate clients
23andme Holding Co's Comment on Sales, Marketing and Customers
23andMe provides direct-to-consumer genetic testing, offering personalized reports on genetic health risks, ancestry, and traits, with over 65 health and carrier status reports available in the U.S. Through its Lemonaid Health telehealth platform, the company enables patients to access licensed healthcare professionals for online consultations, treatment, and medication fulfillment via an online pharmacy. Telehealth consultations are also offered for certain 23andMe genetic reports. Additionally, 23andMe operates a Research business that partners on genetic-based research by monetizing access to genetic and phenotypic data from millions of customers to support disease research and the development of novel therapies.
: In a significant development in the fields of genetics and precision medicine, 23andMe Holding Co. has announced a strategic research collaboration with Mirador Therapeutics on November 20, 2024. This partnership aims to leverage de-identified genetic and phenotypic data to enhance target validation and foster breakthroughs in therapeutics for immunology and inflammation-related diseases. While the collaboration holds promise for innovative treatment options, 23andMe s stock performance indicates varied investor sentiment.The intersection of genetic research and therapeutic development has been a focal point in modern pharmaceutical advancements. The recent collaboration between 23andMe Holding Co. a leade...
23andMe Enhances Brand Awareness with Mathew Knowles Collaboration Amidst Improving Financial Metrics 23andMe, a leading personal genomics and biotechnology company, has announced the appointment of Mathew Knowles as its new brand ambassador. This collaboration aims to increase awareness of the significance of genetic testing in understanding personal health risks. Knowles, known for his work as a music executive and his advocacy in health awareness, will help communicate the benefits of genetic testing to a broader audience. The focus will be on empowering individuals with knowledge about their genetic predispositions, allowing them to make informed health decisions.In addition to this strategic ambassadori...
In an age where genetics and personal wellness increasingly intersect, biotechnology pioneer 23andMe has unveiled an innovative genetic report aimed at elucidating the likelihood of emotional eating among its 23andMe+ Premium members. This new offering seeks to provide members with a scientific basis to understand their genetic predispositions regarding eating habits, specifically those influenced by emotional states. Entering the Arena of Emotional Eating Emotional eating is a phenomenon where individuals turn to food as a response to their feelings, rather than hunger. It is often triggered by stress, boredom, sadness, or other emotional states, leading to overeating or unhealthy food choices. By introduci...
In a groundbreaking endeavor aimed at enhancing lung cancer diagnosis and treatment, twenty prominent lung cancer advocacy organizations have joined forces with 23andMe, a pioneering personal genomics and biotechnology company. This collaboration seeks to establish a comprehensive, open-source database that encompasses heritable genetic factors and patient-reported data associated with lung cancer. The implications of this initiative are profound, not only for cancer research but also for the future direction of 23andMe amid its current revenue challenges.The lung cancer genetics study is designed to collect a diverse array of genetic information and patient experiences, which could significantly advance our...
The Phase 1 clinical trial will involve the evaluation of 23ME-01473 in individuals with advanced solid tumors. This initial stage of trials is crucial in determining the safety and tolerability of the antibody in humans, as well as observing any potential side effects. The data gathered from this trial will lay the foundation for subsequent clinical trials, allowing researchers to assess the efficacy and therapeutic benefits of 23ME-01473 in the treatment of advanced solid tumors.The selection of ULBP6 as a target highlights the power and potential of 23andMe s research platform. This platform, with its vast collection of genetic and phenotypic data, has enabled the company to identify and validate several ...
Recent announcements from genetics and biotechnology company 23andMe have highlighted their participation in the American Association for Cancer Research (AACR) Annual Meeting 2024. The company s presentations on their clinical-stage immuno-oncology programs and cutting-edge research have generated considerable interest. This article aims to ly outline the facts surrounding these presentations and shed light on their potential implications for the field.Key Findings:23andMe has made several significant presentations at the AACR Annual Meeting 2024. The first is an oral presentation on the genetic signature of ULBP6, the target of their experimental drug, 23ME-01473. ULBP6 plays a crucial role in immune regul...
hereby acknowledges the recent achievement of 23andMe Holding Co., a front-runner in the realm of human genetics and biopharmaceuticals. The company has successfully procured clearance from the U.S. Food and Drug Administration (FDA) for their investigational new drug (IND) application for 23ME-01473 (hereafter referred to as 1473), an innovative natural killer (NK) cell activator intended to provide a unique approach to cancer treatment.The FDA clearance is a significant milestone in the journey of 23andMe, highlighting the viability of their novel antibody and acknowledging its potential to address the critical issue of cancer. This antibody, 23ME-01473, strategically targets ULBP6, an activating ligand f...
23andme Holding Co’s Comment on Sales, Marketing and Customers
23andMe provides direct-to-consumer genetic testing, offering personalized reports on genetic health risks, ancestry, and traits, with over 65 health and carrier status reports available in the U.S. Through its Lemonaid Health telehealth platform, the company enables patients to access licensed healthcare professionals for online consultations, treatment, and medication fulfillment via an online pharmacy. Telehealth consultations are also offered for certain 23andMe genetic reports. Additionally, 23andMe operates a Research business that partners on genetic-based research by monetizing access to genetic and phenotypic data from millions of customers to support disease research and the development of novel therapies.
Sources:
23andme Holding Co’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: 23andme Holding Co’s corporate clients.
For your research, we’ve provided 9 tables on 23andme Holding Co corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
78.04 %